卡左双多巴控释片对帕金森病合并睡眠障碍患者精神行为症状、认知障碍及日常生活能力的影响  

Effects of Carbidopa and Levodopa CR Tablets on Psychomotor Symptom,Cognitive Impairment and Daily Living Ability in Patients with Parkinson’s Disease Complicated with Sleep Disorders

作　　者：刘华钊[1] 钟建新[1] 梁彦珊 温清艳 陈克强[1] LIU Huazhao;ZHONG Jianxin;LIANG Yanshan;WEN Qingyan;CHEN Keqiang(Jiangmen Central Hospital,Jiangmen 529000,China)

机构地区：[1]广东省江门市中心医院,广东江门529000

出　　处：《中国医学创新》2020年第9期68-72,共5页Medical Innovation of China

摘　　要：目的:探讨卡左双多巴控释片对帕金森病合并睡眠障碍患者精神行为症状、认知障碍及日常生活能力的影响。方法:选取本院2017年2月-2019年1月帕金森病合并睡眠障碍患者72例,按随机数字表法分为接受多巴丝肼组(多巴丝肼胶囊治疗)与卡左双多巴组(卡左双多巴控释片治疗),每组36例。比较两组精神行为症状、认知能力、日常生活能力、帕金森病症状、睡眠情况及不良反应发生情况。结果:治疗4周内,两组简明精神状态检查量表(MMSE)、蒙特利尔认知评估量表(MoCA)及日常生活活动能力量表(ADL)评分均呈升高趋势(P<0.05)。治疗3、4周后,卡左双多巴组MMSE评分均高于多巴丝肼组(P<0.05)。入组时、治疗1、2、3、4周后,两组MoCA评分比较,差异均无统计学意义(P>0.05)。治疗3、4周后,卡左双多巴组ADL评分均高于多巴丝肼组(P<0.05)。治疗4周后,卡左双多巴组帕金森病评分量表(UPDRS)及匹兹堡睡眠质量指数(PSQI)评分均低于多巴丝肼组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卡左双多巴控释片可明显改善帕金森病合并睡眠障碍患者的精神行为症状及日常生活能力,减轻帕金森病病情并提升睡眠质量。Objective:To investigate the effects of Carbidopa and Levodopa CR Tablets on psychosomatic symptoms,cognitive impairment and daily living ability of patients with Parkinson’s disease complicated with sleep disorder.Method:A total of 72 patients with Parkinson’s disease complicated with sleep disorder in our hospital from February 2017 to January 2019 were selected,and they were divided into Levodopa and Benserazide group(Levodopa and Benserazide Capsule treatment)and the Carbidopa and Levodopa group(Carbidopa and Levodopa CR Tablets treatment)according to the random number table,36 cases in each group.Psychosomatic symptoms,cognitive ability,daily living ability,Parkinson’s disease symptom,sleep and adverse reactions were compared between the two groups.Result:Within 4 weeks of treatment,the scores of mini-mental state examination(MMSE),Montreal cognitive assessment scale(MoCA)and activity of daily life scale(ADL)showed an increasing trend(P<0.05).After 3 and 4 weeks of treatment,the MMSE score of the Carbidopa and Levodopa group were higher than those of the Levodopa and Benserazide group(P<0.05).At enrolled,after 1,2,3,4 weeks of treatment,there were no significant differences in MoCA scores between the two groups(P>0.05).After 3 and 4 weeks of treatment,the ADL scores of the Carbidopa and Levodopa group were higher than those of the Levodopa and Benserazide group(P<0.05).After 4 weeks of treatment,the scores of unified Parkinson’s disease rating scale(UPDRS)and Pittsburgh sleep quality index(PSQI)in the Carbidopa and Levodopa group were lower than those in the Levodopa and Benserazide group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Carbidopa and Levodopa CR Tablets can significantly improve the psychomotor symptoms and daily living ability of patients with Parkinson’s disease and sleep disorders,reduces Parkinson’s disease symptom and improves sleep quality.

关 键 词：卡左双多巴控释片 帕金森病 睡眠障碍 

分 类 号：R742.5[医药卫生—神经病学与精神病学] R740[医药卫生—临床医学]